Biotech IPO window is open but big pharma M&A sets the pace: Bankers

Public markets are starting to reopen for biotech corporations after a number of years of muted exercise.

However the strongest corporations should be extra prone to promote themselves to Massive Pharma moderately than testing investor urge for food in an IPO, based on JPMorgan’s high healthcare dealmakers.

The IPO window has reopened for high-quality biotech corporations, however buyers are way more selective than they have been through the pandemic-era increase, Juha Anjala and Roy Wouters, co-heads of JPMorgan’s EMEA healthcare funding banking, advised CNBC. 

The present market can also be prompting many biotech corporations to pursue a dual-track course of: making ready for an IPO whereas concurrently participating with potential acquirers. 

In some instances, corporations are able to record, solely to be purchased by giant pharmaceutical teams earlier than reaching the general public markets, Wouters stated, including that they’ve suggested on a number of such offers not too long ago.

The pattern displays a broader restoration in healthcare dealmaking, particularly in biopharma, the place drugmakers are below stress to high up their pipelines forward of main patent expirations later this decade and into the early 2030s.

Massive Pharma consumers are effectively funded and more and more prepared to take bigger bets, the bankers stated. Strategic consumers are “on the market seeking to deploy capital” to deepen their pipelines, whereas shareholders are more and more supportive of M&A as a technique to drive progress, stated Anjala.

The result’s a extra aggressive marketplace for the highest-quality biotech belongings, significantly these with differentiated expertise or publicity to giant therapeutic areas similar to oncology, metabolic illnesses, and infectious illnesses. 

For biotech founders and buyers, that creates a stronger exit market than existed a yr or two in the past – however not essentially a easy one. Because the IPO window opens, Massive Pharma’s hunt for progress is anticipated to proceed to set the tempo.

Nonetheless, Anjala and Wouters cautioned that the rebound is not essentially broad-based. Boards and funding committees are closely scrutinizing transactions earlier than signing off on them, and personal capital is turning into extra concentrated. 

“We’re seeing folks take a extra thought of view, and solely actually seeking to again the corporate that is going to be finest at school, first at school,” stated Wouters.

The present surroundings is “offering these corporations with a set of choices, which they only did not have on the IPO facet, or essentially on the M&A facet, even a yr to 2 years in the past,” he added.

That marks a shift from the easy-money interval of 2020 and 2021, when buyers have been prepared to again a number of corporations pursuing comparable targets or applied sciences. As we speak, capital is flowing extra selectively to companies considered as class leaders. 

In a report launched final week, EY stated 38% of recent drug approvals in 2025 have been for first-in-class merchandise. The agency additionally stated the biotech sector is regaining momentum regardless of headwinds like price pressures and looming patent cliffs.

These pressures are pushing corporations towards new financing fashions, together with royalty agreements for pre-market belongings and different progressive contracting buildings, based on EY. 

Deal values and upfront funds are additionally getting greater, Wouters stated. That displays confidence within the goal market, the standard of the asset, and the extent of competitors amongst consumers. 

“Persons are simply prepared to place extra capital in danger by way of the upfront [payment] as a result of they need to, due to the competitors round these belongings,” he stated.

In 2025, there have been seven biopharma offers valued between $5 billion and $15 billion, based on JPMorgan. Almost midway by 2026, there have already been six offers in that vary, suggesting this yr’s run price might outpace final yr. 

Lots of the business’s most commercially profitable medication have come from acquisitions or licensing offers moderately than inner analysis and improvement, highlighting why pharma corporations proceed to make use of M&A to complement their portfolios. 

Shareholders are additionally difficult administration groups to do extra offers, Anjala stated, as money flows stay robust and M&A is seen as a confirmed technique to create worth. The tailwind for strategic acquisitions that may deepen pipelines or deliver synergies is particularly robust, he added. 

Giant pharmaceutical teams, together with GSK and Novartis, have lengthy emphasised a choice for so-called bolt-on offers – acquisitions within the low single-digit billion greenback vary that complement current portfolios with out remodeling the entire enterprise. 

However some current transactions present the willingness to go increased for precedence belongings. GSK not too long ago agreed to purchase U.S. oncology biotech Nuvalent for $10.6 billion, a deal that marks a significant push into most cancers remedies and a departure from its extra typical smaller bolt-on transactions. 

China can also be turning into a extra necessary pressure in international biotech. EY famous that Chinese language corporations now symbolize a real different to U.S. and European biotech hubs, whereas Wouters stated innovation and capital flows in China proceed to speed up. 

“For the previous couple of years, it is at all times been ‘the indicators are good, the grass shoots are there, subsequent yr goes to be a fantastic yr,” Wouters advised CNBC. “It really seems to be like this yr may be a fantastic yr.”